Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus SOX for locally advanced gastric cancer
ChiCTR2400092754Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, oxaliplatin and tegafur in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Tangdu Hospital. Primary endpoint: Major pathological response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tislelizumaboxaliplatintegafur
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400092754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092754.